To the full analysis
Sabra Health Care REIT stock: growth
SBRASabra Health Care REIT reported $774.63M in revenue for fiscal 2025, up 10.2% on the prior year, up 5.3% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
34.8%
per year from 2010 to 2025, per share 15.9%
Earnings (Annual rate)
22.5%
per year from 2010 to 2025, per share 5.4%
Free cash flow (Annual rate)
30.3%
per year from 2010 to 2025, per share 12.1%
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2010 | |
|---|---|---|---|
| Revenue | 5.3% | 12.5% | 34.8% |
| Revenue per share | 2.0% | −1.8% | 15.9% |
| Earnings | 2.4% | 7.0% | 22.5% |
| Earnings per share | −0.9% | −5.4% | 5.4% |
| Free cash flow | 6.9% | 11.2% | 30.3% |
| Free cash flow per share | 3.6% | −2.9% | 12.1% |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2010 | $8.8M | $7.38M | $6.6M |
| 2011 | $84.23M | $12.84M | −$159.8M |
| 2012 | $103.17M | $19.51M | $56.25M |
| 2013 | $134.78M | $33.72M | $62.1M |
| 2014 | $183.52M | $46.95M | $85.34M |
| 2015 | $238.86M | $79.41M | $121.1M |
| 2016 | $260.53M | $70.28M | $176.74M |
| 2017 | $405.65M | $158.38M | −$200.64M |
| 2018 | $623.41M | $279.08M | $451.9M |
| 2019 | $668.19M | $69M | $372.48M |
| 2020 | $598.57M | $138.42M | $249.26M |
| 2021 | $569.55M | −$113.26M | $322.78M |
| 2022 | $624.81M | −$77.61M | $315.73M |
| 2023 | $647.51M | $13.76M | $300.57M |
| 2024 | $703.24M | $126.71M | $310.54M |
| 2025 | $774.63M | $155.61M | $348.61M |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 4 Nov 2026)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.